CRISPR Therapeutics Gains FDA Pediatric Approval for Casgevy as Sales Hit $76M
Resolved · regulation · Occurred · Assessed · 1 sources
This assessment is dated 2026-09-09. Check what remains unresolved below before relying on it.
Which companies' revenue or costs change?
FDA label expansion into pediatric populations widens the addressable patient pool, directly increasing Casgevy commercial uptake and partnership revenue for CRSP and VRTX.
| Question | What the evidence establishes |
|---|---|
| What was reported? | Reported factCasgevy generated $76 million in Q2 sales, representing 78% quarter-over-quarter growth. |
| What else was confirmed? | Reported factThe FDA approved a label expansion for Casgevy covering pediatric patients aged 2 and older. |
| Does the valuation support acting? | UnknownNo stored valuation assumptions for CRSP yet — this is the next research task. |
| What would change the assessment? | UnknownCasgevy Treatment Center Activation Count — Monitor authorized treatment center certifications following pediatric label expansion. |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · Casgevy generated $76 million in Q2 sales, representing 78% quarter-over-quarter growth.
- · The FDA approved a label expansion for Casgevy covering pediatric patients aged 2 and older.
- · CRISPR Therapeutics shares gained nearly 19% across August following Q2 performance.
Public research record
Research framework · page evidenceCompleted event assessment
expanded addressable patient population driving commercial product revenue growth
| Type | Claim | Scope |
|---|---|---|
| Assumption | Casgevy generated $76 million in Q2 sales, representing 78% quarter-over-quarter growth. | 2026-09-09 |
| Interpretation | expanded addressable patient population driving commercial product revenue growth | CRSP |
Countercase, invalidators, and sources
Pediatric treatment center on-boarding accelerates quarterly Casgevy revenue beyond current run-rates.
- · Casgevy Treatment Center Activation Count — Monitor authorized treatment center certifications following pediatric label expansion.
- Why CRISPR Therapeutics Stock Rocked the Market Last Month · 2026-09-08
What remains unresolved
- Base path
- Steady clinical uptake expands commercial sales in line with broadened label parameters.
- Adverse path
- Reimbursement negotiations or hospital processing capacity slow patient treatment initiation schedules.
- Supportive path
- Pediatric treatment center on-boarding accelerates quarterly Casgevy revenue beyond current run-rates.
- · Casgevy Treatment Center Activation Count — Monitor authorized treatment center certifications following pediatric label expansion.next month
Evidence
- Why CRISPR Therapeutics Stock Rocked the Market Last Month2026-09-08
“The company's approved blood disorder treatment Casgevy saw 78% quarter-over-quarter sales growth to $76 million, and the FDA approved its label expansion for pediatric patients aged 2 and older.”
Supports: Casgevy revenue rose 78% QoQ to $76M and received pediatric label expansion from FDA.